ENDEAVOR: Phase 3 trial comparing carfilzomib versus bortezomib in relapsed multiple myeloma | Dr Joseph Mikhael at ASCO 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of ENDEAVOR, a randomised, open-label, phase 3 tri... Author: EMJ Added: 08/26/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts